Login
Companies $ABCL
$11.19 +$0.07 (0.63%) After hours
AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

abcellera.com

What Do They Do?

Licenses antibody drug candidates to pharmaceutical and biotechnology companies, and discovers and develops antibody medicines for patients with unmet medical needs.

How Do They Make Money?

Partners pay royalties tied to sales of licensed drugs, fixed fees for access and discovery research, and milestone payments when specified development or commercial events occur. Research fees are payable at the beginning and end of work phases.

revenue
SegmentShareRevenue
Research fees
Recurring

36%
FY2022: 8.4%
Milestone payments
Sold outright
1.3%
FY2022: 0.2%
Licensing and royalty revenue
Licensed

62%
FY2022: 0.1%

Who Are Their Customers?

Pharmaceutical and biotechnology companies, as well as nonprofit and government organizations, partner with AbCellera on antibody-discovery programs. AbCellera also seeks partners to develop and commercialize its own pipeline medicines.

Do Revenues Turn Into Profits?

No. It lost $146.4M in FY2025.

Operating income, FY2025
−289% of revenue
▲ +31% (Loss) vs FY2024 (−$314.8M, −1092%)
Net income, FY2025
−195% of revenue
▲ +10% (Loss) vs FY2024 (−$162.9M, −565%)
Free cash flow, FY2025
−232% of revenue
▲ +7% (Loss) vs FY2024 (−$187M, −648%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +19%
vs $9M in Q3 FY2025
Net income
▲ +29% (Loss)
vs −$57.1M in Q3 FY2025
  • Jul 29, 2026 Agreed to collaborate with Vertex on antibody treatments The collaboration covers research, development, manufacturing, and commercialization of multispecific T-cell engagers for autoimmune diseases and other conditions.
  • Jun 17, 2026 Agreed with Jazz to discover multispecific antibodies Jazz can choose to develop and commercialize candidates for gastrointestinal cancers and other solid tumors; AbCellera may receive milestone payments and royalties.

Shrinking. Revenue fell 80% in 4 years, from $375.2M in FY2021 to $75.1M in FY2025, about 33% a year.

From partnerships to an internal pipeline The earlier report centered on applying its antibody discovery platform to partner programs and building royalty stakes. The latest report centers on developing AbCellera-owned drug candidates, with programs in clinical trials.

Revenue over time
Research fees Milestone payments Licensing and royalty revenue Royalty revenue
$500M$250M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support